心筋梗塞の世界市場レポート2024年

心筋梗塞の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.1%の年間複合成長率（CAGR）で26億8,000万米ドルに成長すると予想されます。予測期間で予想される成長は、心血管の健康増進を目的とした世界の健康への取り組み、再灌流療法へのアクセスの増加、心血管疾患に対するRNA治療薬の出現、患者中心のケアモデルの採用、医療の高度化など、さまざまな要因に関連している可能性があります。微小血管機能不全への対処とバイオ電子医学の開発に焦点を当てています。予測期間中に予想される主要動向には、心臓血管画像処理の進歩、心臓手術技術の革新、遠隔医療の進歩、診断のための人工知能の統合、リスク予測のためのデジタルバイオマーカーの導入、医療データセキュリティのためのブロックチェーンの利用、AIが含まれます。

心筋梗塞市場の予想される成長は、喫煙者の増加によって促進されると予想されます。喫煙をする人は、紙巻きタバコ、葉巻、パイプのいずれを使用しても、タバコの煙に含まれる化学物質にさらされます。これらの物質は、静脈や動脈の血液を濃くして凝固させ、閉塞を引き起こして心筋梗塞を引き起こす可能性があります。注目すべき例は、英国に本拠を置く国家統計局の2023年9月のデータで、英国の人口のうち25歳から34歳までの層が現在喫煙している割合が最も高く、16.3％、つまり約140万人を占めていることが明らかになった。これは、同年齢層の喫煙率が15.8%で約130万人いた前年からの増加となった。したがって、喫煙者の増加は、心筋梗塞市場の成長を促進する重要な要因です。

心血管疾患の発生率の上昇は、心筋梗塞市場の拡大に寄与すると予想されます。心臓と血管に影響を与える疾患のカテゴリーである心血管疾患は、心臓発作の余波を管理と治療するために心筋梗塞薬の利用を促しています。 2022年 10月の世界心臓連盟によると、心血管疾患（CVD）による死亡者数は、2020年の推定1,890万人から2030年には2,220万人以上に増加すると予測されています。この心血管疾患の増加傾向は、心臓血管疾患の原動力をさらに強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の心筋梗塞市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の心筋梗塞市場規模実績と成長率、2018～2023年
• 世界の心筋梗塞市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の心筋梗塞市場、薬剤クラス別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 抗血小板剤
• 糖タンパク質IIb/IIIa阻害剤
• 抗血栓剤
• ベータアドレナリン遮断薬
• 血管拡大薬
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシン受容体遮断薬
• 鎮痛剤
• 血栓溶解薬
• 世界の心筋梗塞市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 経口
• 注射
• 世界の心筋梗塞市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域と国の分析

• 世界の心筋梗塞市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の心筋梗塞市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心筋梗塞市場の競合情勢
• 心筋梗塞市場企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Novartis AG

第31章 その他の大手と革新的な企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• Merck KGaA
• Daiichi Sankyo Co. Ltd.
• Bio-Rad Laboratories Inc.
• Apotex Inc.
• Siemens Healthcare Diagnostics Limited
• Annexin Pharmaceuticals AB
• Dynavax Technologies Corp
• Heartseed Inc.
• Par Pharmaceutical Companies Inc.
• Tenaya Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Myocardial infarction, commonly known as a heart attack, poses a severe health risk, occurring when the blood flow to a segment of the heart muscle is obstructed, leading to tissue damage or death. This critical condition is often instigated by elevated levels of low-density lipoprotein, hypertension, and tobacco use.

Within the realm of myocardial infarction treatment, various drug classes play pivotal roles in managing and mitigating the condition's impact. These encompass antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents specifically target the prevention of blood clot formation by inhibiting platelet aggregation. Available in both oral and injectable formulations, these agents are accessible through a diverse range of distribution channels, including hospital pharmacies, retail pharmacies, and online platforms.

The myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides myocardial infarction market statistics, including myocardial infarction industry global market size, regional shares, competitors with a myocardial infarction market share, detailed myocardial infarction market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. This myocardial infarction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myocardial infarction market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The expansion observed in the historical period can be attributed to several factors, including the introduction of beta-blockers, the establishment of chest pain centers, the implementation of thrombolytic therapies, advancements in genomic and personalized medicine approaches, and the integration of wearable cardiovascular devices.

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be linked to various factors, including global health initiatives aimed at enhancing cardiovascular health, increased accessibility to reperfusion therapies, the emergence of RNA therapeutics for cardiovascular diseases, the adoption of patient-centered care models, a heightened focus on addressing microvascular dysfunction, and the development of bioelectronic medicine. Major trends expected in the forecast period encompass advancements in cardiovascular imaging, innovations in cardiac surgery techniques, progress in telemedicine, the integration of artificial intelligence for diagnosis, the introduction of digital biomarkers for risk prediction, the utilization of blockchain for healthcare data security, AI-driven drug discovery, and the ongoing innovations in cardiac rehabilitation technologies.

The anticipated growth of the myocardial infarction market is expected to be driven by an increasing number of smokers. Individuals who engage in smoking, whether through cigarettes, cigars, or pipes, expose themselves to chemicals present in tobacco smoke. These substances have the potential to thicken and clot the blood in veins and arteries, leading to blockages that can result in myocardial infarction. A notable example is the data from the UK-based Office for National Statistics in September 2023, revealing that the segment of the UK population aged 25 to 34 years had the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This marked an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Consequently, the growing number of smokers is a significant factor propelling the growth of the myocardial infarction market.

The rising incidence of cardiovascular diseases is expected to contribute to the expansion of the myocardial infarction market. Cardiovascular diseases, a category of disorders affecting the heart and blood vessels, prompt the utilization of myocardial infarction drugs to manage and treat the aftermath of heart attacks. According to the World Heart Federation in October 2022, the number of cardiovascular disease (CVD) deaths is projected to increase from an estimated 18.9 million in 2020 to over 22.2 million in 2030. This upward trend in cardiovascular diseases further underscores the driving force behind the growth of the myocardial infarction market.

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body's immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.

Major companies in the myocardial infarction market are focused on developing advanced devices that utilize technology, such as SmartAssist dual-sensor technology, to address acute right heart failure and to maximize their profits in the market. SmartAssist dual-sensor technology refers to a system equipped with two sensors designed to gather and monitor advanced metrics in a medical device. For instance, in October 2022, Abiomed, a US-based provider of medical technology, received FDA approval for its Impella RP Flex with SmartAssist. It is implanted via the internal jugular vein; it allows patient mobility and features dual-sensor technology for optimal patient management and weaning. The Impella RP platform includes percutaneous right heart mechanical circulatory support technologies designed for native heart recovery. Impella RP with SmartAssist has received approval from the U.S. FDA for the treatment of right heart failure or decompensation after procedures including left ventricular assist device implantation, myocardial infarction, and heart transplant.

In December 2022, Johnson & Johnson, a leading US-based healthcare products conglomerate, finalized the acquisition of Abiomed for a notable sum of $16.6 billion. This strategic acquisition positions Johnson & Johnson MedTech to integrate heart recovery solutions from Abiomed into its existing Biosense Webster electrophysiology division. By doing so, Johnson & Johnson aims to augment its offerings in the rapidly growing cardiovascular sector. Abiomed, renowned for its pioneering clinical research, specializes in the treatment of acute myocardial infarction, further enriching Johnson & Johnson's comprehensive cardiovascular solutions portfolio.

Major companies operating in the myocardial infarction market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Boehringer Ingelheim GmbH, Merck KGaA, Daiichi Sankyo Co. Ltd., Bio-Rad Laboratories Inc., Apotex Inc., Siemens Healthcare Diagnostics Limited, Annexin Pharmaceuticals AB, Dynavax Technologies Corp, Heartseed Inc., Par Pharmaceutical Companies Inc., Tenaya Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Acesion Pharma ApS, Applied Therapeutics Inc., Athersys Inc., Cardurion Pharmaceuticals Inc., Verve Therapeutics Inc., Serca Pharmaceuticals AS

North America was the largest region in the myocardial infarction market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myocardial infarction market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myocardial Infarction Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myocardial infarction market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myocardial infarction ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myocardial infarction market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Antiplatelet Agents; Glycoprotein IIb/IIIa Inhibitors; Antithrombotic Agents; Beta-adrenergic Blockers; Vasodilators; Angiotensin-converting Enzyme (ACE) Inhibitors; Angiotensin-receptor Blockers; Analgesics; Thrombolytics
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myocardial Infarction Market Characteristics

3. Myocardial Infarction Market Trends And Strategies

4. Myocardial Infarction Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Myocardial Infarction Market Size and Growth

• 5.1. Global Myocardial Infarction Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Myocardial Infarction Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Myocardial Infarction Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Myocardial Infarction Market Segmentation

• 6.1. Global Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antiplatelet Agents
• Glycoprotein IIb/IIIa Inhibitors
• Antithrombotic Agents
• Beta-adrenergic Blockers
• Vasodilators
• Angiotensin-converting Enzyme (ACE) Inhibitors
• Angiotensin-receptor Blockers
• Analgesics
• Thrombolytics
• 6.2. Global Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Injectable
• 6.3. Global Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Myocardial Infarction Market Regional And Country Analysis

• 7.1. Global Myocardial Infarction Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Myocardial Infarction Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Myocardial Infarction Market

• 8.1. Asia-Pacific Myocardial Infarction Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Myocardial Infarction Market

• 9.1. China Myocardial Infarction Market Overview
• 9.2. China Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Myocardial Infarction Market

• 10.1. India Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Myocardial Infarction Market

• 11.1. Japan Myocardial Infarction Market Overview
• 11.2. Japan Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Myocardial Infarction Market

• 12.1. Australia Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Myocardial Infarction Market

• 13.1. Indonesia Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Myocardial Infarction Market

• 14.1. South Korea Myocardial Infarction Market Overview
• 14.2. South Korea Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Myocardial Infarction Market

• 15.1. Western Europe Myocardial Infarction Market Overview
• 15.2. Western Europe Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Myocardial Infarction Market

• 16.1. UK Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Myocardial Infarction Market

• 17.1. Germany Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Myocardial Infarction Market

• 18.1. France Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Myocardial Infarction Market

• 19.1. Italy Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Myocardial Infarction Market

• 20.1. Spain Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Myocardial Infarction Market

• 21.1. Eastern Europe Myocardial Infarction Market Overview
• 21.2. Eastern Europe Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Myocardial Infarction Market

• 22.1. Russia Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Myocardial Infarction Market

• 23.1. North America Myocardial Infarction Market Overview
• 23.2. North America Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Myocardial Infarction Market

• 24.1. USA Myocardial Infarction Market Overview
• 24.2. USA Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Myocardial Infarction Market

• 25.1. Canada Myocardial Infarction Market Overview
• 25.2. Canada Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Myocardial Infarction Market

• 26.1. South America Myocardial Infarction Market Overview
• 26.2. South America Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Myocardial Infarction Market

• 27.1. Brazil Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Myocardial Infarction Market

• 28.1. Middle East Myocardial Infarction Market Overview
• 28.2. Middle East Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Myocardial Infarction Market

• 29.1. Africa Myocardial Infarction Market Overview
• 29.2. Africa Myocardial Infarction Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Myocardial Infarction Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Myocardial Infarction Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Myocardial Infarction Market Competitive Landscape And Company Profiles

• 30.1. Myocardial Infarction Market Competitive Landscape
• 30.2. Myocardial Infarction Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson Services Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Myocardial Infarction Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Abbott Laboratories
• 31.5. Boehringer Ingelheim GmbH
• 31.6. Merck KGaA
• 31.7. Daiichi Sankyo Co. Ltd.
• 31.8. Bio-Rad Laboratories Inc.
• 31.9. Apotex Inc.
• 31.10. Siemens Healthcare Diagnostics Limited
• 31.11. Annexin Pharmaceuticals AB
• 31.12. Dynavax Technologies Corp
• 31.13. Heartseed Inc.
• 31.14. Par Pharmaceutical Companies Inc.
• 31.15. Tenaya Therapeutics Inc.

32. Global Myocardial Infarction Market Competitive Benchmarking

33. Global Myocardial Infarction Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Myocardial Infarction Market

35. Myocardial Infarction Market Future Outlook and Potential Analysis

• 35.1 Myocardial Infarction Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Myocardial Infarction Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Myocardial Infarction Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer